Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

robot
Abstract generation in progress

Eli Lilly’s stock closed at $878.24 after the company announced a significant $2.75 billion licensing and research deal with Insilico Medicine. This comes as Lilly aims to diversify beyond its weight-loss drugs, with new trial data showing positive results for its psoriatic arthritis treatment combination and its eczema drug. The company continues to navigate competition and analyst adjustments to sales estimates for the obesity-drug sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin